Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 13/20 | 0.76 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.76 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | ATM | Q13315 | 1/20 | 0.70 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.67 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.63 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6344501 | 0.90 | PTGS2 (0.76) | PTGS2CHRNA7PTGS1 | |
| SCHEMBL27485652 | 0.89 | PTGS2 (0.65) | PTGS2CHRNA7PTGS1ALOX5 | |
| SCHEMBL5236666 | 0.89 | RPA1 (0.72) | PTGS2MEN1KMT2APTGS1ALOX5 | |
| SCHEMBL27485627 | 0.88 | PTGS2 (0.69) | PTGS2CHRNA7PTGS1ALOX5 | |
| SCHEMBL3873219 | 0.88 | CHRNA7 (0.80) | PTGS2CHRNA7MEN1KMT2AATM | |
| SCHEMBL5430032 | 0.88 | CA9 (0.74) | PTGS2CHRNA7PTGS1PPP1CAALOX5 | |
| SCHEMBL9203245 | 0.88 | MEN1 (0.70) | PTGS2CHRNA7MEN1KMT2AATM | |
| SCHEMBL28294492 | 0.87 | CHRNA7 (0.77) | PTGS2CHRNA7PTGS1 | |
| SCHEMBL6342214 | 0.86 | PTGS2 (1.00) | PTGS2CHRNA7PTGS1 | |
| SCHEMBL6350064 | 0.85 | PTGS2 (0.82) | PTGS2CHRNA7PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109748872-A | The design and synthesis of the morpholine derivative antitumoral compounds of one kind skeleton containing diaryl pyrazole | 南京大学 | 2019-05-14 | — | — | CN | disclosed |
| US-RE44048-E1 | 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-YL]benzenesulfonamide for the treatment of inflammation or an inflammation-associated disorder | G.D. SEARLE LLC (US) | 2013-03-05 | — | — | US | disclosed |
| EP-1682143-A2 | COMBINATIONS COMPRISING AN HSP90 INHIBITOR AND A PHOPHODIESTERASE INHIBITOR FOR TREATING OR PREVENTING NEOPLASIA | Pharmacia Corporation (US) | 2006-07-26 | — | — | EP | disclosed |
| US-6951949-B2 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation | PHARMACIA CORPORATION (US) | 2005-10-04 | — | — | US | disclosed |
| US-20050131050-A1 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflamation | G.D. SEARLE & CO. (US) | 2005-06-16 | — | — | US | disclosed |
| WO-2005044194-A2 | TREATMENT OR PREVENTION OF NEOPLASIA BY USE OF AN Hsp90 INHIBITOR | PHARMACIA CORPORATION (US) | 2005-05-19 | — | — | WO | disclosed |
| WO-2005041879-A2 | COMBINATIONS COMPRISING AN Hsp90 INHIBITOR AND A PHOPHODIESTERASE INHIBITOR FOR TREATING OR PREVENTING NEOPLASIA | PHARMACIA CORPORATION (US) | 2005-05-12 | — | — | WO | disclosed |
| US-20040192930-A1 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation | G.D. SEARLE & CO. (US) | 2004-09-30 | — | — | US | disclosed |
| US-6716991-B1 | REACTING ETHYL DIFLUOROACETATE AND 4'-CHLOROACETOPHENONE PRODUCING 4,4-DIFLUORO-1-(4-(CHLORO)PHENYL)-BUTANE-1,3-DIONE AND REACTING WITH 4-SULPHONAMIDOPHENYL HYDRAZINE HYDROCHLORIDE | G. D. SEARLE & CO. | 2004-04-06 | — | — | US | disclosed |
| US-6586603-B1 | Forming 4-(5-(4-chlorophenyl)-3-trifluoromethyl)-1H-pyrazol-1 -yl)benzenesulfonamide used as antiinflammatory agents; side effect reduction | G.D. SEARLE & CO. | 2003-07-01 | — | — | US | disclosed |
| US-6156781-A | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation | G. D. SEARLE & CO. (US) | 2000-12-05 | — | — | US | disclosed |
| EP-0731795-B1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 1999-12-22 | — | — | EP | disclosed |
| EP-0923933-A1 | Substituted pyrazolyl benzenesulfonamides for use in the treatment of inflammation | G.D. SEARLE & CO. (US) | 1999-06-23 | — | — | EP | disclosed |
| CN-1202828-A | Substituted pyrzolyl benzenesulfonanides for use in veterinary | SEARLE & CO (US) | 1998-12-23 | — | — | CN | disclosed |
| EP-0854723-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR USE IN VETERINARY THERAPIES AS ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1998-07-29 | — | — | EP | disclosed |
| US-5760068-A | NONSTEROIDAL ANTIINFLAMMATORY AGENTS WITH REDUCED SIDE EFFECTS | G.D. SEARLE & CO. (US) | 1998-06-02 | — | — | US | disclosed |
| US-5756529-A | ANTIINFLAMMATORY | G.D. SEARLE & CO. (US) | 1998-05-26 | — | — | US | disclosed |
| WO-1997011704-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR USE IN VETERINARY THERAPIES AS ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1997-04-03 | — | — | WO | disclosed |
| EP-0731795-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-09-18 | — | — | EP | disclosed |
| WO-1995015316-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G. D. SEARLE & CO. (US) | 1995-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192930-A1 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation | IL6, HRH4, CCR2 | PTGS2 279/4885CHRNA7 2147/4885MEN1 4817/4885 |
| US-20050131050-A1 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflamation | IRAK2, IRAK4, IRAK3 | PTGS2 230/4885CHRNA7 3450/4885MEN1 4773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.